[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Nasus Pharma Ltd. reported that it has begun a Phase 2 clinical study of its product candidate NS002, with the first participant already dosed. This step marks a move into a more advanced stage of human testing, where the company will further evaluate NS002’s performance and safety in patients. The update was provided through a press release dated November 18, 2025, which is attached to this report as an exhibit.

Insights

Biopharma development analyst

Nasus Pharma advances NS002 into Phase 2, signaling clinical progress but with no new data yet.

Nasus Pharma Ltd. disclosed that it has initiated a Phase 2 clinical study of its candidate NS002, and that the first participant has been dosed as of a press release dated November 18, 2025. Moving into Phase 2 generally means the program cleared earlier-stage testing and is now being studied in a larger, more defined patient group, although specific design details are not included in this summary.

This milestone indicates continued development commitment to NS002, but the information provided does not include efficacy, safety results, or timelines for completion. The actual impact will depend on future clinical outcomes and any additional disclosures in later reports.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025 (Report No. 2)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On November 18, 2025, Nasus Pharma Ltd. (the “Company”), issued a press release titled “Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release issued on November 18, 2025 by Nasus Pharma Ltd. titled “Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: November 18, 2025	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

FAQ

What did Nasus Pharma Ltd. (NSRX) announce in this Form 6-K?

Nasus Pharma Ltd. announced that it has started a Phase 2 clinical study of its product candidate NS002 and has already dosed the first participant, as described in a press release furnished with the report.

What stage of development is NS002 now in at Nasus Pharma (NSRX)?

NS002 has entered the Phase 2 clinical study stage, meaning it is being evaluated in a more advanced phase of human clinical testing than early-stage studies.

When did Nasus Pharma (NSRX) report dosing the first participant with NS002 in Phase 2?

The company reported the initiation of the Phase 2 study and first participant dosing for NS002 in a press release dated November 18, 2025, which is attached as Exhibit 99.1.

Where can investors find more details about the NS002 Phase 2 study by Nasus Pharma?

More details are contained in the press release titled “Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed,” which is furnished as Exhibit 99.1 to this report.

Does this Nasus Pharma (NSRX) Form 6-K include financial or earnings data?

No, this report focuses on the clinical development update for NS002 and references a press release; it does not present financial or earnings figures.